Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
| 対象疾患 | ALS |
|---|---|
| 相 | 第3相 |
| スポンサー | Shionogi |
| ステータス | 早期終了 |
| 参加者数 | 384 名 |
| 介入（薬剤） | MT-1186 |
| 開始日 | 2020年11月13日 |
| 完了日 | 2023年9月29日 |
| 結果公開日 | 2025年3月27日 |
概要
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48:
CAFS Score at Week 48
| Edaravone 105 mg (Once Daily) | 187.2 Units on a scale |
|---|---|
| Edaravone 105mg (2 Weeks On/Off ) | 184.2 Units on a scale |
| p-value | 0.777 |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Ed — Shionogi
- Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic L — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis — Shionogi
- Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral — Shionogi